Transcarent To Acquire Accolade (ACCD) for $7.03 per share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall St set to gain on tech rebound, Middle East in focus
- SpaceX prices historic IPO at $135/share in largest ever new listing
- Oil drops as Trump cancels planned strikes against Iran
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Axsome Therapeutics (AXSM) PT Raised to $380 at Jefferies
Transcarent To Acquire Accolade
January 8, 2025 8:30 AM ESTCombined company creates industry leading platform with more than 1,400 employer and payer clients, with shared focus on consumer empowerment
Transcarents Generative AI WayFinding and care experiences combined with Accolades Advocacy, Expert Medical Opinion, and Primary Care will deliver on the promise of One Place for Health and Care
Accolade shareholders to receive $7.03 per share in cash
SAN FRANCISCO and SEATTLE, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Transcarent, the One Place for Health and Care, and Accolade (NASDAQ: ACCD), a leader in health... More
